Page 90 - Read Online

Cendrós et al. J Transl Genet Genom 2020;4:210-20 Journal of Translational
DOI: 10.20517/jtgg.2020.21 Genetics and Genomics

Original Article Open Access

The influence of CYP enzymes and ABCB1 on
treatment outcomes in schizophrenia: association of

CYP1A2 activity with adverse effects

Marc Cendrós , María Jesús Arranz , Mercè Torra , Rafael Penadés , Alex Gonzalez-Rodriguez , Mercè
6
2,3
4
3,5
1,2
Brunet , Josefina Perez-Blanco , Laura Ibáñez , Alex Serra , Rosa Catalán 3,5
4
2
3,7
2
1 Eugenomic S.L., Barcelona 08012, Spain.
2 Fundació Docència i Recerca Mútua Terrassa, Terrassa 08221, Spain.
3 Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Institut de Recerca Biomèdica Sant Pau (IIB-Sant Pau),
Barcelona 08041, Spain.
4 Pharmacology & Toxicology Unit, Department Biochemistry & Molecular Genetics, Hospital Clínic of Barcelona, Barcelona
08036, Spain.
5 Barcelona Clinic Schizophrenia Unit (BCSU), Neurosciences Institute, Hospital Clínic of Barcelona, University of Barcelona,
IDIBAPS, Barcelona 08036, Spain.
6 Department Mental Health, Parc Taulí University Hospital, Sabadell, Barcelona, Sabadell 08208, Spain.
7 Department Psychiatry, Hospital de la Santa Creu i Sant Pau, Barcelona 08041, Spain.
Correspondence to: Dr. María Jesús Arranz, Fundació Docència i Recerca Mútua Terrassa, c\Sant Antoni 19, Terrassa 08221,
Spain. E-mail: mjarranz@mutuaterrassa.es; Dr. Rosa Catalán, Barcelona Clinic Schizophrenia Unit (BCSU), Neurosciences
Institute, Hospital Clínic of Barcelona, University of Barcelona, IDIBAPS, c/Roselló, 140, Barcelona 08036 Spain.
E-mail: rcatalan@clinic.cat
How to cite this article: Cendrós M, Arranz MJ, Torra M, Penadés R, Gonzalez-Rodriguez A, Brunet M, Perez-Blanco J, Ibáñez L,
Serra A, Catalán R. The influence of CYP enzymes and ABCB1 on treatment outcomes in schizophrenia: association of CYP1A2
activity with adverse effects. J Transl Genet Genom 2020;4:210-20. http://dx.doi.org/10.20517/jtgg.2020.21

Received: 28 Feb 2020 First Decision: 10 Apr 2020 Revised: 13 May 2020 Accepted: 28 May 2020 Available online: 24 Jun 2020
Science Editor: Tjitske Kleefstra Copy Editor: Xin-Qian Li Production Editor: Jing Yu

Abstract
Aim: Genetic variants on metabolic and transport enzymes are good candidates to explain inter-individual
differences in response to antipsychotics. The aim of this study is to evaluate and compare the influence of
the CYP2D6 , CYPC19, CYP1A2 and ABCB1 variants on plasma levels, treatment response and side effects of
antipsychotics.

Methods: Twenty polymorphisms in selected genes were genotyped in 318 patients diagnosed with schizophrenia,
schizoaffective or delusional disorder treated with antipsychotics (clozapine, olanzapine, paliperidone, risperidone,
aripiprazole and quetiapine). Plasma drug levels were determined after 6 weeks of treatment. The Positive and
Negative Symptoms Scale (PANSS) and UKU scale of side effects were recorded at baseline and after 12 weeks

© The Author(s) 2020. Open Access This article is licensed under a Creative Commons Attribution 4.0
International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long
as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license,
and indicate if changes were made.

www.jtggjournal.com